ORBi: van de Putte L. B. A. - Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

Reference : Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal anti...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Rheumatology
	To cite this reference:	http://hdl.handle.net/2268/72425

Title :	Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
Language :	English
Author, co-author :	van de Putte, L. B. A. [ > > ]
	Rau, R. [ > > ]
	Breedveld, F. C. [ > > ]
	Kalden, J. R. [ > > ]
	Malaise, Michel [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >]
	van Riel, P L C M [ > > ]
	Schattenkirchner, M. [ > > ]
	Emery, P. [ > > ]
	Burmester, G. R. [ > > ]
	Zeidler, H. [ > > ]
	Moutsopoulos, H. M. [ > > ]
	Beck, K. [ > > ]
	Kupper, H. [ > > ]
Publication date :	2003
Journal title :	Annals of the Rheumatic Diseases
Publisher :	BMJ Group
Volume :	62
Issue/season :	12
Pages :	1168-1177
Peer reviewed :	Yes (verified by ORBi)
Audience :	International
ISSN :	0003-4967
e-ISSN :	1468-2060
City :	London
Country :	United Kingdom
Keywords :	[en] Antibodies, Monoclonal ; Antirheumatic Agents ; Tumor Necrosis Factor-alpha
Abstract :	[en] OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in disease modifying antirheumatic drug (DMARD) refractory patients with longstanding, active rheumatoid arthritis (RA). METHODS: During a 12 week, double blind, placebo controlled study, 284 patients were randomly allocated to receive weekly subcutaneous injections of adalimumab 20 mg (n = 72), 40 mg (n = 70), or 80 mg (n = 72) or placebo (n = 70) without concomitant DMARDs. RESULTS: Adalimumab significantly improved the signs and symptoms of RA for all efficacy measures. ACR20 responses with adalimumab were significant at each assessment versus placebo (p</=0.01). Additionally, ACR responses with adalimumab were achieved more rapidly than with placebo, with 82/115 (71%) of the ultimate ACR20 response rate to adalimumab treatment achieved at week 2. At week 12, for adalimumab 20, 40, and 80 mg, ACR20 response rates were 50.7%, 57.1%, and 54.2%, respectively, versus 10.0% for placebo (p</=0.001 for all comparisons); ACR50 rates were 23.9%, 27.1%, and 19.4%, respectively, versus 1.4% for placebo (p</=0.001 for all comparisons); and ACR70 rates were 11.3%, 10.0%, and 8.3%, respectively, versus 0.0% for placebo (p</=0.05 for all comparisons). All adalimumab doses significantly improved all ACR core criteria at all assessments. The 40 mg and 80 mg doses provided similar benefit. Adalimumab at all doses was generally well tolerated, with only mild or moderate adverse events. Completion rates were 87% for adalimumab and 67% for placebo. CONCLUSIONS: Adalimumab given as monotreatment to patients with longstanding, severe RA refractory to traditional DMARDs produced a rapid, sustained response and was safe and well tolerated, with no dose limiting side effects.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/72425

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	Malaise_2003_AnnRheumDis_1168-1177.pdf		Publisher postprint	595.59 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5